

ASTRAZENECA PLC
Form 6-K
July 31, 2014

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934

For the month of July 2014

Commission File Number: 001-11960

AstraZeneca PLC

2 Kingdom Street, London W2 6BD

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): _____

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes No

If "Yes" is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b): 82- _____

4 PIPELINE UPDATE - ASTRAZENECA DEVELOPMENT PIPELINE,

Edgar Filing: ASTRAZENECA PLC - Form 6-K

30 JUNE 2014

NMEs

Phase III / Pivotal / Registration

Submission dates shown for assets in Phase III and beyond.

As disclosure of compound information is balanced by the business need to maintain confidentiality, information in relation to some compounds listed here has not been disclosed at this time.

| Compound | Mechanism | Area Under Investigation | Date Commenced Phase | Estimated Filing | | | |
|-------------------------------|---|-------------------------------------|----------------------|------------------|----------|----------|----------|
| | | | | US | EU | Japan | China |
| Cardiovascular and Metabolism | | | | | | | |
| Brilinta / Brilique1 | ADP receptor antagonist | arterial thrombosis | | Launched | Launched | Filed | Launched |
| Epanova# | omega-3 free fatty acids | hypertriglyceridaemia | | Approved | | | |
| Farxiga / Forxiga2 | SGLT-2 inhibitor | diabetes | | Launched | Launched | Launched | Filed |
| Myalept roxadustat# | leptin analogue hypoxia-inducible factor inhibitor | lipodystrophy anaemia in CKD / ESRD | Q3 2014 | Launched 2018 | 2015 N/A | N/A N/A | 2016 |
| Oncology | | | | | | | |
| AZD9291¶ | EGFR tyrosine kinase inhibitor | advanced T790M+ NSCLC | Q2 2014 | 2015 | 2015 | 2015 | 2017 |
| Caprelsa | VEGFR / EGFR tyrosine kinase inhibitor with RET kinase activity | medullary thyroid cancer | | Launched | Launched | Q3 2014 | Filed |
| MEDI4736# PACIFIC | anti-PD-L1 MAb | stage III NSCLC | Q2 2014 | 2017 | 2020 | 2020 | |
| MEDI4736# ATLANTIC¶ | anti-PD-L1 MAb | 3rd line NSCLC | Q1 2014 | 2016 | 2017 | 2017 | |
| moxetumomab pasudotox# | anti-CD22 recombinant immunotoxin | hairy cell leukaemia | Q2 2013 | 2018 | 2018 | | |
| olaparib | PARP inhibitor | BRCAm PSR ovarian cancer | | Filed | Filed | | |
| olaparib SOLO-1 | PARP inhibitor | 1st line BRCAm ovarian cancer | Q3 2013 | 2017 | 2017 | 2017 | 2018 |
| olaparib SOLO-2 | PARP inhibitor | BRCAm PSR ovarian cancer | Q3 2013 | 2016 | 2016 | 2016 | 2016 |
| olaparib GOLD | PARP inhibitor | 2nd line gastric cancer | Q3 2013 | | | 2017 | 2018 |
| olaparib OlympiA | PARP Inhibitor | adjuvant breast cancer | Q2 2014 | 2020 | 2020 | 2020 | 2021 |
| olaparib OlympiAD | PARP inhibitor | metastatic breast cancer | Q2 2014 | 2016 | 2016 | 2016 | |
| selumetinib# | MEK inhibitor | | Q4 2013 | 2017 | 2017 | | |

Edgar Filing: ASTRAZENECA PLC - Form 6-K

| | | | | | | |
|-----------------------|-----------------|-------------------------------|---------|------|------|------|
| SELECT-1 | | 2nd line KRAS+ NSCLC | | | | |
| selumetinib# ASTRA | MEK inhibitor | differentiated thyroid cancer | Q3 2013 | 2017 | 2017 | |
| selumetinib# SUMIT | MEK inhibitor | uveal melanoma | Q2 2014 | 2015 | 2015 | |
| tremelimumab# | anti-CTLA-4 MAb | mesothelioma | Q2 2014 | 2017 | 2017 | 2017 |

Phase III / Pivotal / Registration (continued)

| Compound | Mechanism | Area Under Investigation | Date Commenced Phase | Estimated Filing | | | |
|--|--|---|----------------------|------------------|----------|-------|-------|
| | | | | US | EU | Japan | China |
| Respiratory, Inflammation and Autoimmunity | | | | | | | |
| benralizumab# CALIMA, SIROCCO, ZONDIA | anti-IL-5R MAb | severe asthma | Q4 2013 | 2016 | 2016 | | |
| benralizumab# TERRANOVA, GALATHEA | anti-IL-5R MAb | COPD | Q3 2014 | 2018 | 2018 | | |
| brodalumab# AMAGINE-1,2,3 | anti-IL-17R MAb | psoriasis | Q3 2012 | ++ | ++ | | |
| brodalumab# AMVISION-1,2 | anti-IL-17R MAb | psoriatic arthritis | Q1 2014 | ++ | ++ | | |
| lesinurad | selective uric acid reabsorption inhibitor (URAT1) | chronic treatment of patients with gout | Q4 2011 | Q4 2014 | Q4 2014 | | n/a5 |
| PT003 GFF | LAMA / LABA | COPD | Q2 2013 | 2015 | 2016 | | |
| PT001 GP | LAMA | COPD | Q2 2013 | 2015 | 2016 | | |
| Infection | | | | | | | |
| CAZ AVI# RECLAIM | cephalosporin / beta lactamase inhibitor | serious infections | Q1 2012 | N/A | Q4 2014 | 2015 | 2016 |
| CAZ AVI# REPROVE | cephalosporin / beta lactamase inhibitor | hospital-acquired pneumonia / ventilator-associated pneumonia | Q2 2013 | N/A | 2017 | 2017 | 2018 |
| Zinforo# | extended spectrum cephalosporin with affinity to penicillin-binding proteins | pneumonia / skin infections | | N/A | Launched | N/A | Filed |
| Neuroscience | | | | | | | |
| Movantik# | oral peripherally-acting mu-opioid receptor antagonist | opioid-induced constipation | | Filed | Filed | | |

Edgar Filing: ASTRAZENECA PLC - Form 6-K

Partnered product.

¶ Registrational Phase II/III study.

++ Filing is the responsibility of the partner.

1 Brilinta in the US; Brilique in rest of world.

2 Farxiga in the US; Forxiga in rest of world.

3 First patient enrolled in June and dosed in July 2014.

4 First patient dosed in July 2014.

5 Regulatory approval no longer being sought in China. This market will be served by RDEA3170.

NMEs

Phases I and II

| Compound | Mechanism | Area Under Investigation | Phase | Date Commenced Phase | Estimated Filing | | | |
|-------------------------------|--|--------------------------------|-------|----------------------|------------------|----|-------|-------|
| | | | | | US | EU | Japan | China |
| Cardiovascular and Metabolism | | | | | | | | |
| tenapanor (AZD1722)# | NHE3 inhibitor | ESRD-Pi / CKD with T2DM1 | II | Q1 2013 | | | | |
| AZD4901 | hormone modulator | polycystic ovarian syndrome | II | Q2 2013 | | | | |
| AZD1979 | melanin-concentrating hormone (MCH) receptor | obesity | I | Q2 2014 | | | | |
| MEDI6012 | LCAT | arterial thrombosis | I | Q1 2012 | | | | |
| MEDI8111 | Rh-factor II | trauma / bleeding | I | Q1 2014 | | | | |
| Oncology | | | | | | | | |
| AZD1775# | WEE-1 inhibitor | ovarian cancer | II | Q4 2012 | | | | |
| AZD2014 | mTOR serine / threonine kinase inhibitor | solid tumours | II | Q1 2013 | | | | |
| AZD4547 | FGFR tyrosine kinase inhibitor | solid tumours | II | Q4 2011 | | | | |
| MEDI-551# | anti-CD19 MAb | CLL / DLBCL | II | Q1 2012 | | | | |
| MEDI-573# | anti-IGF MAb | metastatic breast cancer | II | Q2 2012 | | | | |
| selumetinib# | MEK inhibitor | 2nd line KRAS- NSCLC | II | Q1 2013 | | | | |
| AZD5363# | AKT kinase inhibitor | breast cancer | II | Q1 2014 | | | | |
| volitinib# | MET tyrosine kinase inhibitor | papillary renal cell carcinoma | II | Q2 2014 | | | | |
| AZD1208 | PIM kinase inhibitor | haematological malignancies | I | Q1 2012 | | | | |
| AZD5312# | androgen receptor inhibitor | prostate cancer | I | Q2 2014 | | | | |
| AZD6738 | ATR serine / threonine kinase | CLL / head & neck | I | Q4 2013 | | | | |

Edgar Filing: ASTRAZENECA PLC - Form 6-K

| | | | | |
|--------------------------------------|---|-----------------------------|---|---------|
| AZD8186 | inhibitor PI3 kinase beta inhibitor | solid tumours | I | Q2 2013 |
| AZD9150# | STAT3 inhibitor | haematological malignancies | I | Q1 2012 |
| MEDI-565# | anti-CEA BiTE MAb | solid tumours | I | Q1 2011 |
| MEDI0639# | anti-DLL-4 MAb | solid tumours | I | Q2 2012 |
| MEDI0680 | anti-PD-1 MAb | solid tumours | I | Q4 2013 |
| MEDI3617# | anti-ANG-2 MAb | solid tumours | I | Q4 2010 |
| MEDI4736# + tremelimumab | anti-PD-L1 MAb + anti-CTLA-4 MAb | solid tumors | I | Q4 2013 |
| MEDI4736# + dabrafenib + trametinib2 | anti-PD-L1 MAb + BRAF inhibitor + MEK inhibitor | melanoma | I | Q1 2014 |
| MEDI4736# + Iressa | anti-PD-L1 MAb + EGFR inhibitor | NSCLC | I | Q2 2014 |
| MEDI4736# + MEDI0680 | anti-PD-L1 MAb + anti-PD-1 MAb | solid tumours | I | Q2 2014 |
| MEDI-551# + rituximab3 | anti-CD19 MAb + anti-CD20 MAb | haematological malignancies | I | Q2 2014 |

NMEs

Phases I and II (continued)

| Compound | Mechanism | Area Under Investigation | Phase | Date Commenced Phase | US | Estimated Filing | | |
|--|-----------------------------------|------------------------------|-------|----------------------|----|------------------|-------|-------|
| | | | | | | EU | Japan | China |
| Oncology (continued) | | | | | | | | |
| MEDI6469# | murine anti-OX40 MAb | solid tumours | I | Q1 2006 | | | | |
| moxetumomab pasudotox# | anti-CD22 recombinant immunotoxin | pALL | I | Q3 2008 | | | | |
| tremelimumab + Iressa | anti-CTLA-4 MAb + EGFR inhibitor | NSCLC | I | Q2 2014 | | | | |
| Respiratory, Inflammation and Autoimmunity | | | | | | | | |
| AZD2115# | MABA | COPD | II | Q2 2012 | | | | |
| AZD9412# (SNG001) | inhaled interferon | asthma / COPD | II | Q1 2010 | | | | |
| anifrolumab# | anti-IFN-alpha MAb | RSLE | II | Q1 2012 | | | | |
| brodalumab# | anti-IL-17R MAb | asthma | II | Q2 2013 | | | | |
| mavrilimumab# | anti-GM-CSFR MAb | rheumatoid arthritis | II | Q1 2010 | | | | |
| MEDI2070# | anti-IL-23 MAb | Crohn's disease | II | Q1 2013 | | | | |
| MEDI7183# | anti-a4b7 MAb | Crohn's disease / ulcerative | II | Q4 2012 | | | | |

Edgar Filing: ASTRAZENECA PLC - Form 6-K

| | | | | | |
|--------------|--|--|----|---------|--|
| | | colitis | | | |
| MEDI9929# | anti-TSLP MAb | asthma | II | Q2 2014 | |
| PT010 | LAMA / LABA | COPD | II | Q2 2014 | |
| | / ICS | | | | |
| RDEA3170 | selective uric acid reabsorption inhibitor (URAT1) | chronic management of hyperuricaemia in patients with gout | II | Q3 2013 | |
| sifalimumab# | anti-IFN-alpha MAb | SLE | II | Q3 2008 | |
| tralokinumab | anti-IL-13 MAb | asthma / IPF | II | Q1 2008 | |
| AZD1419# | TLR9 agonist | asthma | I | Q3 2013 | |
| AZD7594 | inhaled SGRM | asthma / COPD | I | Q3 2012 | |
| AZD7624 | inhaled P38 inhibitor | COPD | I | Q1 2013 | |
| AZD8848# | inhaled TLR7 agonist | asthma | I | Q2 2012 | |
| MEDI-551# | anti-CD19 MAb | multiple sclerosis | I | Q3 2012 | |
| MEDI4920 | anti-CD40L MAb | primary Sjögren's syndrome | I | Q2 2014 | |
| MEDI5872# | anti-B7RP1 MAb | SLE | I | Q4 2008 | |
| | Infection | | | | |
| AZD5847 | oxazolidinone anti-bacterial inhibitor | tuberculosis | II | Q4 2012 | |
| CXL# | beta lactamase inhibitor / cephalosporin | MRSA | II | Q4 2010 | |
| ATM AVI | monobactam / beta lactamase inhibitor | targeted serious bacterial infections | I | Q4 2012 | |
| AZD0914 | GyrAR | serious bacterial infections | I | Q4 2013 | |

NMEs

Phases I and II (continued)

| Compound | Mechanism | Area Under Investigation | Phase | Date Commenced Phase | Estimated Filing | | | |
|-----------------------|----------------------------------|--------------------------------|-------|----------------------|------------------|----|-------|-------|
| | | | | | US | EU | Japan | China |
| Infection (continued) | | | | | | | | |
| MEDI-550 | pandemic influenza virus vaccine | pandemic influenza prophylaxis | I | Q2 2006 | | | | |
| MEDI-559 | paediatric RSV vaccine | RSV prophylaxis | I | Q4 2008 | | | | |

Edgar Filing: ASTRAZENECA PLC - Form 6-K

| | | | | |
|--------------|---------------------------------|---|----|---------|
| MEDI4893 | MAb binding to S. aureus toxin | hospital-acquired pneumonia / serious S. aureus infection | I | Q1 2013 |
| MEDI7510 | RSV sF+GLA-SE | prevention of RSV disease in older adults | I | Q2 2014 |
| MEDI8897# | anti-RSV MAb-YTE | passive RSV prophylaxis | I | Q2 2014 |
| Neuroscience | | | | |
| AZD3241 | myeloperoxidase inhibitor | multiple system atrophy ⁵ | II | Q2 2012 |
| AZD5213 | histamine-3 receptor antagonist | Tourette's syndrome / neuropathic pain | II | Q4 2013 |
| AZD3293# | beta-secretase inhibitor | Alzheimer's disease | I | Q4 2012 |
| AZD6423 | NMDA antagonist | suicidal ideation | I | Q3 2013 |
| MEDI1814 | anti-amyloid beta MAb | Alzheimer's disease | I | Q2 2014 |

Partnered product.

1 Fluid retention indication for tenapanor terminated in Q2.

2 MedImmune-sponsored study in collaboration with GSK.

3 MedImmune-sponsored study in collaboration with Genentech.

4 Original programme terminated in 2013. Programme now reinitiated.

5 Multiple system atrophy is now the lead indication for this molecule.

Line Extensions

| Compound | Mechanism | Area Under Investigation | Date Commenced Phase | Estimated Filing | | | |
|---|-------------------------|---|----------------------|------------------|------|-------|-------|
| | | | | US | EU | Japan | China |
| Cardiovascular and Metabolism | | | | | | | |
| Brilinta/ Brilique1 EUCLID | ADP receptor antagonist | outcomes study in patients with peripheral artery disease | Q4 2012 | 2016 | 2016 | 2017 | 2017 |
| Brilinta/ Brilique1 PEGASUS-TIMI 54 | ADP receptor antagonist | outcomes study in patients with prior myocardial infarction | Q4 2010 | 2015 | 2015 | 2015 | 2017 |
| Brilinta/ Brilique1 SOCRATES | ADP receptor antagonist | outcomes study in patients with stroke or TIA | Q1 2014 | 2016 | 2016 | 2016 | 2017 |
| Brilinta/ Brilique1 THEMIS | ADP receptor antagonist | outcomes study in patients with Type 2 diabetes | Q1 2014 | 2017 | 2017 | 2018 | 2018 |

Edgar Filing: ASTRAZENECA PLC - Form 6-K

| | | | | | | | |
|---|---|---|---------|----------|----------|-------|-------|
| | | and CAD, but without a previous history of MI or stroke | | | | | |
| BydureonDual Chamber Pen | GLP-1 receptor agonist | diabetes | | Approved | Filed | Filed | |
| BydureonEXSCEL | GLP-1 receptor agonist | outcomes study | Q2 2010 | 2018 | 2018 | 2018 | |
| Bydureonweekly suspension | GLP-1 receptor agonist | diabetes | Q1 2013 | 2015 | 2015 | | |
| Farxiga/ Forxiga2 DECLARE-TIMI 58 | SGLT-2 inhibitor | outcomes study | Q2 2013 | 2020 | 2020 | | |
| KombiglyzeXRFD / KomboglyzeFDC3 | DPP-4 inhibitor / metformin FDC | diabetes | | Launched | Launched | | Filed |
| OnglyzaSAVOR-TIMI 53 | DPP-4 inhibitor | outcomes study | Q2 2010 | Filed | Filed | | 2015 |
| saxagliptin / dapagliflozin FDC | DPP-4 inhibitor / SGLT-2 inhibitor FDC | diabetes | Q2 2012 | 2015 | 2015 | | |
| XigduoXRFD /Xigduo FDC4 | SGLT-2 inhibitor / metformin FDC | diabetes | | Filed | Launched | | |
| Oncology Caprelsa | VEGFR / EGFR tyrosine kinase inhibitor with RET kinase activity | differentiated thyroid cancer | Q2 2013 | 2016 | 2016 | 2016 | |
| FaslodexFALCON | oestrogen receptor antagonist | 1st line advanced breast cancer | Q4 2012 | 2016 | 2016 | 2016 | 2016 |
| IressaIMPRESS | EGFR tyrosine kinase inhibitor | treatment beyond progression | Q1 2012 | | 2015 | 2015 | 2015 |
| Respiratory, Inflammation and Autoimmunity Symbicort5 | ICS / LABA | Breath Actuated Inhaler asthma / COPD | | | | | |

Edgar Filing: ASTRAZENECA PLC - Form 6-K

Line Extensions (continued)

| Compound | Mechanism | Area Under Investigation | Date Commenced Phase | Estimated Filing | | | |
|------------------|-------------------------------|--|----------------------|------------------|----------|---------|----------|
| | | | | US | EU | Japan | China |
| Neuroscience | | | | | | | |
| Diprivan# | sedative and anaesthetic | conscious sedation | | N/A | Launched | Q4 2014 | Launched |
| Gastrointestinal | | | | | | | |
| Entocort | glucocorticoid steroid | Crohn's disease / ulcerative colitis | | Launched | Launched | 2015 | N/A |
| linaclotide# | GC-C receptor peptide agonist | irritable bowel syndrome with constipation (IBS-C) | | N/A | N/A | N/A | 2015 |
| Nexium | proton pump inhibitor | peptic ulcer bleeding | | Launched | Launched | N/A | Launched |

Partnered product.

1 Brilinta in the US; Brilique in rest of world.

2 Farxiga in the US; Forxiga in rest of world.

3 Kombiglyze XR in the US; Komboglyze FDC in the EU.

4 Xigduo XR FDC in the US; Xigduo FDC in the EU.

5 Development of a new BAI device is ongoing.

Terminations (discontinued projects between 1 April and 30 June 2014)

| NME / Line Extension | Compound | Reason for Discontinuation | Area Under Investigation |
|----------------------|-----------|----------------------------|--------------------------|
| NME | AZD47211 | Safety / efficacy | COPD |
| NME | AZD50691 | Safety / efficacy | asthma |
| NME | MEDI8968# | Safety / efficacy | COPD / HS |
| NME | MEDI9287 | economic | avian influenza |

Partnered product.

1 Termination decision made July 2014.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AstraZeneca PLC

Edgar Filing: ASTRAZENECA PLC - Form 6-K

Date: 31 July 2014

By: /s/ Adrian Kemp
Name: Adrian Kemp
Title: Company Secretary